A 5' Dystrophin Duplication Mutation Causes Membrane Deficiency of a-Dystroglycan in a Family with X-linked Cardiomyopathy. lourr~nl of Molecular and Cellular Cardiology (1997) 29, 3175-3188. 5'-mutations in the dystrophin gene can result in cardiomyopathy without clinically-apparent skeletal myopathy. The effect of dystrophin mutations on the assembly and stability of the dystrophin associated protein (DAP) complex in human heart are not fully understood. The molecular defect in the dystrophin complex was explored in a family with an X-linked pedigree and severe dilated cardiomyopathy. Dystrophin gene analysis demonstrated a 5' duplication involving exons 2-7, which encodes the N-terminal actin binding domain of dystrophin. Ribonuclease protection and PCR assays demonstrated a reduction in muscle promoter transcribed dystrophin mRNA in the heart compared to skeletal muscle. A deficiency of cardiac dystrophin protein was observed by Western blot and lack of membrane localization by immunocytochemistry. The cardiac expression of the dystrophin related protein utrophin was increased, and the 43 kDa (p-dystroglycan), 50 kDa (a-sarcoglycan) and 59 kDa (syntrophin) dystrophin associated proteins (DAPs) were co-isolated and present in nearly normal amounts in the membrane. However, cardiac dystrophin deficiency and increased utrophin expression were associated with loss of extracellular 156 kDa dystrophin associated glycoprotein (a-dystroglycan) binding to the cardiomyocyte membrane, a-Dystroglycan is responsible for linkage of the dystrophin complex to the extracellular matrix protein laminin. Therefore, 5' dystrophin mutations can reduce cardiac dystrophin mRNA, protein expression, and dystrophin function in X-linked cardiomyopathy (XLCM). The presence of membrane-associated p-dystroglycan, a-sarcoglycan, syntrophin, and utrophin are insufficient to maintain cardiac function. This XLCM family has a 5' dystrophin gene mutation resulting in cardiac dystrophin deficiency and a loss of a-dystroglycan membrane binding.
Introduction
and in some families appear to have a genetic etiology (Michels et al., 1992) . Duchenne and Familial cardiomyopathy and idiopathic dilated Becker muscular dystrophies (DMDIBMD) are excardiomyopathy (IDC) are conditions associated amples where a mutation in the gene encoding the with a high mortality (Goldstein and Brown, 1988) , 1993; Franz et d., 1995) . Several reports now suggest that most patients with severe heart failure and mild or inapparent skeletal myopathy have mutations in the 5' region of the dystrophin gene. The proposed mechanisms which may explain the XLCM phenotype in these families include either mutations which cause diminished expression of cardiac dystrophin (Muntoni et al., 1995, Milasin et al., 19961, or cardiac also affect cardiac muscle and play an important role in XLCM. The autosomal homologue of dystrophin, dystrophin related protein (DRP) or utrophin, has also been shown to associate with the DAP complex in the membrane (Matsumura et al., 1992) . Data in small-caliber skeletal muscle in the mdx mouse has led to the hypothesis that utrophin may be substituted for dystrophin as an approach to therapy in DMDIBMD (Matsumura and Campbell, 1994) . The organization of DAPs and utrophin may therefore influence the phenotypic presentation of dystrophin mutations in diseases like XLCM. In this report, we have analysed cardiac and skeletal muscle dystrophin, utrophin, and DAP expression and membrane affinity in a family with X-linked cardiomyopathy. Our results suggest that a mutation in the 5' region of the dystrophin gene can cause muscle-promoter-derived mRNA and protein to be reduced in heart compared with skeletal muscle. This abnormality is associated with an increase in cardiac utrophin, and a loss of a-dystroglycan binding with the cardiomyocyte membrane.
sensitive changes in N-terminal amino acid sequence (~r t i z -~o p e z et al., 1997). What remains
Materials and Methods
cellular matrix protein laminin (Ervasti and Campbell, 1991 j. Loss of dystrophin can cause destabilization and loss of the DAP complex at the cell membrane (Ohlendieck et al., 1991a The importance of this complex has been demonstrated by the fact that mutations in either dystrophin or the dystrophin associated glycoproteins [SO kDa DAG (a-sarcoglycanj, 43 kDa DAG (Psarcoglycan), and 3 5 kDa DAG (y-sarcoglycan)] can affect skeletal muscle causing muscular dystrophies (Hoffman et al.. 198 7; Roberds et al.. 1994; Bonneman et al., 1995; Lim et al.. 1995; Noguchi et al., 1995) . A review by Towbin (1995) suggested that a reduction in the abundance of cardiac 156 kDa a-dystroglycan may occur in some cases of XLCM. Thus. the organization of the DAP complex may Dystrophin is found at the inner membrane surface of cardiac and skeletal muscle fibers and is 
LW
bound to a dystrophin-associated protein (DAP) complex. This complex forms a structural network which stabilizes the muscle membrane and links intracellular actin microfilaments to the extra-as previously described (Bies et al., 1992a) . Dystrophin cDNA probe 9.7 (ATCC, Rockville, MD, USA) which spans exons 1-9 (cDNA bp 1-1538), detected the mutation, and the other probes showed no abnormality. Purified DNA was digested with Hind 111, separated by 1% agarose gel electrophoresis, and transferred to nitrocellulose membrane (Genescreen, Dupont, Boston, MA, USA). Probes used in this study were labeled with 32P-dCTP (New England Nuclear, Boston, MA, USA) using a random hexamer priming kit (Pharmacia Biotech Inc., Piscataway, NJ, USA). Exon numbering of Hind I11 fragments detected on Southern blot follows the convention established by Koenig et al., (1989) . Analysis of band intensity was performed using a scanning densitometer (Helena Labs, Beumont, TX, USA) on the autoradiograms.
Tissue sources
Fresh heart muscle was obtained at the time of cardiac transplantation and immediately frozen in liquid nitrogen-colled isopentane. Biopsy specimens from left biceps muscle were prepared in a similar fashion. Control skeletal muscle samples were obtained from gastrocnemius muscle from two diabetic subjects post-leg-amputation. Control cardiac tissues were obtained from three explanted hearts at the time of transplantation from non-dystrophic (ischemic) cardiomyopathy. All tissues were pathological specimens obtained at the time of surgery with informed consent per institutional guidelines.
PCR analysis of dystrophin cDNA
Evaluation of dystrophin mRNA transcribed from the genomic mutation (exon 2-7 duplication) was performed by reverse transcription of heart and skeletal muscle RNA into cDNA with a dystrophinspecific primer, followed by nested PCR amplification. Primers flanking the duplication (in exons 1 and 10) were selected for an initial round of reverse transcription PCR. Total RNA was prepared as described by Chirgwin (1979) . Five pg of RNA was incubated with 50 ng of reverse primer (bases 1229-12 53) in exon 1 0 for reverse transcription into cDNA (Bies et al., 1992) . The cDNA product was diluted to 5 pl and PCR performed using 500 ng exon 1 forward primer (cDNA sequence 36-61) and 450 ng exon 1 0 reverse primer (cDNA sequence 1229-1253) for 30 cycles. This reaction was diluted 1 to 50 and a 1 p1 aliquot was used as a template for subsequent PCR reactions. Figure 4 shows the location of primers used in PCR reactions 1-4. Reaction 1 utilized primers in exon 1 (cDNA sequence 218-242) and exon 8 (cDNA sequence 9 6 7-9 8 6), spanning the duplication, to synthesize a large 1387 base pair fragment. Reaction 2 utilized a forward primer in exon 1 (cDNA sequence 2 18-242) and a reverse primer in duplicated exon 4 (cDNA sequence 428-452) to synthesize both 852 bp (2a) and 235 bp (2b) fragments from each of the exon 4 annealing sites. Reaction 3 utilized a reverse primer in exon 8 (cDNA sequence 9 6 7-9 8 6) and a forward primer in duplicated exon 7 (cDNA sequence 784-808) to synthesize both 8 2 1 bp (3a) and 203 bp (3b) fragments from each of the exon 7 annealing sites. Reaction 4 utilized a forward exon 7 primer (cDNA sequence 784-808) and a reverse exon 4 primer (cDNA sequence 4 2 8 4 5 2 ) predicted to synthesize a 286 bp fragment from the center of the duplication.
Dystrophin gene transcription is regulated in a tissue and developmentally specific manner by multiple promoterlenhancer elements in the 5' region. The majority of cardiac and skeletal muscle dystrophin expression is driven by the "muscle" promoter, though expression from "brain" promoters has been described (Feener et al., 1989; Nude1 et al., 1989; Bies et al., 1992b) . To test for transcripts derived from muscle and non-muscle dystrophin promoters, PCR amplification was performed with promoter-specific exon 1 forward primers for the muscle, cortical brain, and Purkinje transcripts according to previous reports (Bies et al., 1992b; Holder et al., 1996) . Ten p1 of all PCR reactions were analysed on 3% NuSieve agarose gels (FMC Bioproducts, Rockland, ME, USA) containing 0.2 mglml of ethidium bromide prior to photography.
Subcloning and sequencing
The PCR products were subcloned directly into the TA cloning vector kit (Invitrogen Cor., San Diego, CA, USA). Plasmid DNA containing dystrophin cDNA inserts were purified (Maxiprep, Promega Cor., Madison, WI, USA) and sequenced using T7 and SP6 primers with a Sequenase version 2.0 sequencing kit (United States Biochemical Cor., Cleveland, OH, USA).
Ribonuclease protection assay
A 2 3 5 nt riboprobe spanning dystrophin exons 1-4 (cDNA bases 218-452) was selected to determine the abundance of dystrophin mRNA in affected heart and skeletal muscle (Holder et al., 1996) . The probe starts with the last 22 bp from the muscle promoter exon 1, and ends with the first 58 bp from exon 4. Hybridization to the duplicated dystrophin transcript should protect two equal fragments; one normal sized (235 nt) fragment corresponding to hybridization to the 5'-end of the mutant transcript containing exon 1-4 sequence, and one smaller 2 1 3 nt fragment of approximately equal intensity hybridizing to the downstream duplication sequence junction containing exons 2, 3 and 4. The 22 nt of sequence in the riboprobe from exon 1 should not hybridize to the exon 7 sequence which preceeds exon 2 at the central portion of the duplicated transcript.
Hybridization to dystrophin transcript in control tissues should detect a 235 nt fragment. The low level transcription from the brain (Bies et al., 1992b) and Purkinje promoter (Holder et al., 1996) in control muscle tissues should also detect a small amount of the 2 1 3 nt (exon 2-4) fragment due to mismatch from brain exon 1 and Purkinje exon 1 (Holder et al., 1996) . Ribonuclease protection assay (RPA I1 kit, Promega Corp.) of dystrophin transcripts was performed using 5 pg of total RNA as previously described (Holder et al., 1996) . To assess equal RNA loading, 5 pg of total RNA from affected and control heart and skeletal muscle was examined by Northern blots using a GAPDH 32P-labeled cDNA probe (ATCC, Rockville, MD, USA). RPA samples were analysed by electrophoresis in an 8% polyacrylamide gel and exposed to x-ray film for 4 days.
Western blot analysis
Whole tissue heart and skeletal muscle tissue homogenates (Bies et al., 1992c) , and microsomal membranes from human cardiac tissue were prepared (Ohlendieck et al., 1991b) . Proteins were resolved electrophorectically in 3-12% polyacrylamide gradient gels which were then electrophoretically transferred to nitrocellulose membrane (0.2 pm, Bio-Rad Laboratories Inc.. Hercules, CA, USA) (Bies et al., 1 9 9 2~) .
The antibodies used in this study are as follows: rabbit polyclonal anti-dystrophin antibody (Bies et al., 1992c) at 1:500 dilution in Tris (10 mM; ph 8.0) buffered saline, 0.05% Tween 20 (TBST), anti-utrophin (Ohlendieck et al., 1991a) rabbit polyclonal antibody at 1: 100, anti-1 56 DAG (Ibraghimov-Beskrovnaya et al., 1992) sheep polyclonal antibody at 1:50, anti-59 DAP (Ohlendieck et al., 1991b) sheep polyclonal antibody at 1:50, anti-50 DAG (Roberds et al., 1993) sheep polyclonal antibody at 1:500, and anti-43 DAG (Ohlendieck et al., 199lb) sheep polyclonal antibody at 1:50 dilution. Immunoreactive bands were detected with secondary antibodies coupled to alkaline phosphatase (Sigma Chemical Co.) (Bies et al., 1992c) or to horseradish peroxodase using the enhanced chemiluminescent method (Amersham Corp.). Protein concentrations of tissue homogenates were determined by BCA protein assay (Pierce, Rockford, IL, USA) and 24 pg was loaded in each lane. Equal sample loading was assessed by staining the gel with Coomassie blue and insuring a consistent density of the myosin band in each lane as previously described (Maeda et al., 1996) . A scanning densitometer (Bio-Rad Laboratories Inc.) was used to analyse dystrophin, utrophin, and DAP band intensity relative to controls.
lmmunocytochemistry and histopathology
Unfixed frozen samples of heart and skeletal muscle were cut into 6 pm cryosections and placed on Superfrost microscope slides (Fischer Scientific, Pittsburgh, PA, USA). The slides were blocked with 3% BSA in phosphate buffered saline (PBS, pH 7.4) for 20 min at room temperature and then incubated with anti-dystrophin antibody (Bies et al., 1992c) or anti-vinculin antibody (Maeda et al., 1997) for 2 h. Slides were incubated with secondary antibody for 1 h; tetramethylrhodamine isothiocyanate (TRITC) conjugated anti-rabbit IgG antibody (1:80, Sigma Chemical Co.) The slides were washed with PBS and mounted with 90% glycerol in PBS. Staining with secondary antibodies alone was used as a control for non-specific fluorescence. Stained sections were photographed under uv light with a Nikon microscope. Light microscopy of hemotoxylin and eosin stained sections were performed on 6-pm sections of 10% buffered neutral formalin fixed paraffin blocks of affected tissue.
DNA analysis
Southern blot analysis using dystrophin cDNA probes showed a 5' gene duplication. Probe 9.7 demonstrated the presence of nine Hind I11 the heart. This abnormality was associated with a loss of a-dystroglycan association with the cardiomyocyte membrane. Skeletal muscle dystrophin mRNA, protein abundance, and localization to the sarcolemma were not as severely afffected. Sufficient dystrophin expression in skeletal muscle accompanied by continuous immunolocalization at the sarcolemma in all myocytes was probably capable of maintaining partial integrity of the skeletal muscle DAP complex. The concept that some e L ---L -l A ---. .-e -P d-.-t-,,h:,   , , , ,tt,,. .,t, phenotype in mdx mice (Wells et al., 1995) . Therefore, differences in dystrophin abundance and membrane association probably account for most of the differences in disease severity in heart v skeletal muscle.
Utrophin can also bind and maintain membrane association of the DAP complex in skeletal muscle (Tinsley et al., 1996) . Skeletal muscle utrophin was mildly increased in the family studied, and therefore could potentially stabilize the skeletal muscle DAP membrane complex and attenuate the development of skeletal myopathy. However, we found cardiac utrophin expression was significantly increased and co-isolated in cardiac microsomal membranes with some components of the DAP complex. The cardiac utrophinIDAP complex appeared unable to maintain the membrane binding affinity of a-dystroglycan, or prevent the development of cardiomyopathy. This observation could be due to possible differences in utrophin expression in cardiac and skeletal myocytes. a-Dystroglycan is localized to the cardiac membrane, and is believed to link the dystrophin cytoskeletal complex to the extracellular matrix protein laminin (Ervasti and Campbell, 1991) . Utrophin has been localized to the intercalated disc and T-tubules of bovine and mouse heart (Klietsch et al., 1993 : Pons et al., 1994 , and laminin is absent from the intercalated disc (Klietsch et al., 1993) . Therefore, the interaction of DAPs with other cytoskeletal elements like utrophin at the intercalated disc may lack the appropriate structural organization or subcellular localization to maintain DAP (a-dystroglycan) binding in the heart. The recent observation that a truncated utrophin transgene is capable of maintaining skeletal muscle membrane DAPs, and reduce the dystrophic pheneotype in mdx mouse, has not been proven to be effective in cardiac tissues (Tinsley et al., 1996) .
There is growing evidence that XLCM is commonly associated with 5' dystrophin gene mutations. The 5' mutation in this study is located in the same general region of the dystrophin gene described in other XLCM reports (Muntoni et al., 1993; Milasin et al., 1995; Ortiz-Lopez et al., 1997) , and had likely occurred via a cross-over event with breakpoints in intron 1 and intron 7. As in our report, the other families studied had some elevation of serum CK and subclinical muscle degeneration1 regeneration was probably present. However, the lack of severe skeletal muscle symptoms suggests function in the heart has been reported as one possible mechanism (Ortiz-Lopez et al., 199 7). In two other families, complete loss of muscle promoter activity may explain the phenotype. In these cases, selective activation of the brain or Purkinje promoters appeared to provide adequate dystrophin transcription in skeletal muscle, but not in the heart (Milasin et al., 1995; Mutoni et al., 1995b) . The current study expands the possible mechanisms involved in phenotypic heart and skeletal muscle disease expression. The same mutant dystrophin transcript was present in both tissues, yet dystrophin immunolocalized at the membrane in skeletal muscle, but was almost absent in heart. The mutation may have caused a cardiac-sensitive change in dystyropin function. However, part of the difference was also likely due to an alteration of dystrophin abundance in the heart. In other XLCM reports, cardiac dystrophin expression was selectively reduced (and skeletal muscle expression maintained) due to differential activity of nonmuscle promoters in the absence of normal muscle promoter activity. This mechanism was probably not the cause of low cardiac dystrophin mRNA in our family. In this study, the amount of musclepromoter-derived dystrophin mRNA in heart and skeletal muscle was different. Cardiac dystrophin mRNA was almost undetectable, and skeletal muscle dystrophin mRNA was present in near normal amounts. Differential activity of non-muscle promoters did not appear to play a major role in dystrophin expression. This observation suggests that the mutation breakpoints could have involved unidentified regulatory elements for dystrophin muscle promoter activity or dystrophin mRNA stability in the heart. Therefore, several potential mechanisms have been identified which could contribute to the unusual XLCM phenotype. These include a reduction in cardiac dystrophin mRNA expression or stability, abnormal dystrophin protein stabilitylfunction, and the potential salutary effect of increased skeletal muscle utrophin. The current literature for XLCM does not allow us to conclude that a n y one of these mechanisms predominate. However, w h e n dystrophin is abnormally expressed in the heart, the final common pathway may be a loss of membrane bound a-dystroglycan and development of cardiomyopathy. Studies on other families will be required to determine whether a defect in cardiac membrane a-dystroglycan binding is a unique feature of XLCM.
